GO
Loading...

Enter multiple symbols separated by commas

Stocks Sanofi SA

More

  • July 30- Amgen Inc on Thursday reported higher-than-expected second-quarter profit and revenue, helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting, and the company raised its full-year forecasts. Excluding special items, Amgen earned $2.57 per share, topping analysts' average expectations by 14 cents, according to Thomson...

  • MannKind slumps after Sanofi details Afrezza sales Thursday, 30 Jul 2015 | 11:52 AM ET

    Shares of MannKind stumbled Thursday after the French pharmaceutical giant Sanofi detailed low initial sales for a fast-acting, inhaled insulin developed by MannKind. Sanofi licensed Afrezza's worldwide marketing rights from MannKind Corp., and the drugmakers launched the insulin in February. Valencia, California- based MannKind has no other drugs on...

  • UPDATE 1-Sanofi's diabetes sales slow, Genzyme's jump Thursday, 30 Jul 2015 | 4:54 AM ET

    PARIS, July 30- Sanofi reported lower second quarter sales for its strategic diabetes division on Thursday, hurt by continued pricing pressure in the United States, but it's biotech arm Genzyme recorded another quarter of double-digit growth, enabling the French drugmaker to beat forecasts overall. Forced to agree to increased rebates to maintain market...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients. U.S. regulators on Friday approved the first of the new medicines, Praluent from Regeneron Pharmaceuticals Inc and Sanofi SA.

  • NEW YORK— French drugmaker Sanofi said Monday it will pay up to $300 million to buy a thyroid cancer drug from British competitor AstraZeneca. Sanofi's Genzyme unit will pay $165 million for Caprelsa, and it agreed to make another $135 million in milestone payments based on regulatory development and sales targets. U.S.-traded shares of Sanofi fell 43 cents to...

  • New heart drugs come in more expensive than expected Monday, 27 Jul 2015 | 6:02 AM ET

    *Sanofi, Novartis set high prices for Praluent, Entresto. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems. Sanofi and Regeneron, which won U.S. approval on Friday for Praluent to treat stubbornly high...

  • WASHINGTON, July 24- The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients with a hereditary form of the condition and those with cardiovascular disease. The FDA ruling came just hours after European regulators recommended...

  • WASHINGTON— The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. The drug from Sanofi and Regeneron Pharmaceuticals Inc. offers an important new option for millions of patients at high risk of heart disease. But the drug's sky-high...

  • *Sanofi/ Regeneron PCSK9 drug Praluent endorsed by EMA. *Praluent to compete with Amgen's rival product Repatha. LONDON, July 24- A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.

  • LONDON, July 24- A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen. Amgen's Repatha was formally approved by the European Commission on Tuesday after a positive EMA opinion in May and Praluent is likely to be cleared by the Commission after a...

  • Plant 'milkers' seek molecules for medicines and make-up Wednesday, 22 Jul 2015 | 8:43 AM ET

    *Companies including BASF and Chanel have teamed up with PAT. LARONXE, France, July 22- A quiet village in eastern France is home to an unusual greenhouse. Several major companies, including German chemicals group BASF and French cosmetics maker Chanel, have teamed up with Plant Advanced Technologies in the hope of securing privileged access to the so-called...

  • Europe approves Amgen's first-in-class cholesterol drug Tuesday, 21 Jul 2015 | 10:49 AM ET

    WASHINGTON— Amgen on Tuesday received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades. The U.S. Food and Drug Administration is scheduled to make a decision on a similar drug from Sanofi and Regeneron Pharmaceuticals this Friday.

  • July 21- Amgen Inc's cholesterol fighting drug was approved by the European Commission, giving the keenly anticipated treatment a head start over a rival drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA. Amgen did not immediately reveal when the drug would be available or its pricing strategy. Amgen's drug is designed for biweekly doses of...

  • PARIS, July 15- Sanofi will adopt a simplified structure centred around five global business units starting in January 2016 to promote growth, the French drugmaker said on Wednesday, as it prepares a new strategic plan to be unveiled in November. The composition of Sanofi's executive committee remains unchanged, the company said. The reorganisation is...

  • Seprafilm, developed by Genzyme, is used to reduce abnormal internal scarring following surgery, by separating tissues and organs while they heal. The FDA and Genzyme, which was bought by Sanofi in 2011, were not immediately available for comment. FDA database of Manufacturer and User Facility Device Experience cites at least nine reports that link Seprafilm...

  • July 7- Consumer watchdog Public Citizen said it petitioned the U.S. health regulators to withdraw approval of Sanofi SA's Seprafilm and order a recall, saying the surgical implant has been associated with side effects including death. Seprafilm, developed by Genzyme, is used to reduce abnormal internal scarring following surgery, by separating tissues and...

  • BASEL, Switzerland, June 29- Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. A copy of the letter to EU Health Commissioner Vytenis Andriukaitis from Richard Bergstrom, director general of the European...

  • June 26- Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. Celladon said if it were to liquidate during the third quarter ending September, the net cash available for distribution to shareholders would be about $25 million- $30 million.

  • New drug compound may beat malaria with single $1 dose Wednesday, 17 Jun 2015 | 1:00 PM ET

    LONDON, June 17- Scientists have discovered a new anti-malarial compound that could treat patients with a single $1 dose, including those with strains of the mosquito-borne disease that are resistant to current drugs. In a vote of confidence for the project, German drugmaker Merck KgAA has secured the right to develop and commercialize the compound, assuming...